<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2311">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04522986</url>
  </required_header>
  <id_info>
    <org_study_id>ADR-001-1919</org_study_id>
    <nct_id>NCT04522986</nct_id>
  </id_info>
  <brief_title>An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection</brief_title>
  <acronym>COVID-19</acronym>
  <official_title>An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rohto Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rohto Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and efficacy of ADR-001 are evaluated in Patients with Severe Pneumonia caused by
      SARS-CoV-2 infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with Severe Pneumonia caused by SARS-CoV-2 infection are enrolled to the study.
      Adipose-derived mesenchymal stem cells (AD-MSCs) are administered once a week, total four
      times intravenously. Safety and efficacy of AD-MSCs are evaluated for 12 weeks after first
      administer.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Adverse Event</measure>
    <time_frame>12 weeks</time_frame>
    <description>Adverse events which appear in subjects with ADR-001 treatment are evaluated.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Severe Acute Respiratory Syndrome Coronavirus 2</condition>
  <arm_group>
    <arm_group_label>Mesenchymal stem cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 times dose of Mesenchymal stem cell</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal stem cell</intervention_name>
    <description>1*10^8 cells are administered once a week, total four times intravenously.</description>
    <arm_group_label>Mesenchymal stem cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  SARS-CoV-2 infection is confirmed on antigen test or PCR test

          -  Pulmonary infiltrative shadow is confirmed on chest X-ray test

          -  Mechanical ventilation is being utilized, or Acute Respiratory Failure whose PaO2 is
             not being achieved to 80 mmHg in spite of High-flow oxygen therapy

        Exclusion Criteria:

          -  Continue treatment for Pneumonia before SARS-CoV-2 infection

          -  SOFA score &gt;= 15

          -  Infection type on DIC diagnosis criteria &gt;= 4

          -  Deep Venous Thrombosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuji Fujino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Osaka University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rohto Pharmaceutical Co., Ltd.</last_name>
    <phone>+81-3-6823-6014</phone>
    <email>adr-001@rohto.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <contact>
      <last_name>Yuji Fujino, MD</last_name>
      <phone>+81-3-6823-6014</phone>
      <email>adr-001@rohto.co.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>August 20, 2020</last_update_submitted>
  <last_update_submitted_qc>August 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

